D-Fi

Phase 3Biologic

CCastle Creek Biosciences, LLC.

D-Fi is one of 47 biologic programs targeting Treatment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TreatmentActive, not recruiting

TreatmentPhase 3

Active, not recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Biltricide

Bayer

Preclinical

4 2

D-Fi

CCastle Creek Biosciences, LLC.

Phase 3

1 3

Dexilant

Takeda

Preclinical

2 4

Alfenta

Jazz Pharmaceuticals

Preclinical

1 5

Niclocide

Bayer

Preclinical

1 6

Minipress

Pfizer

Preclinical

1 7

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 8

Clomid

Ferring

Preclinical

1 9

Aurlumyn

BBTG International Inc.

Preclinical

1 10

Lotemax

PPharmos

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2042

Phase 3Active, not recruiting

Treatment

NCT06892639

Clinical

Trials by Indication[1]

Treatment1 trial

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

Active, not recruiting·CCastle Creek Biosciences, LLC.·Phase 3·NCT06892639·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for D-Fi. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D-Fi compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D-Fi. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Castle Creek Biosciences, LLC. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CCastle Creek Biosciences, LLC.

D-Fi

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2042

Trials by Indication[1]

Treatment1 trial

References

Drug Info

Quick Facts

Related News